Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Trial of Ivosidenib and FLAG Chemotherapy in Relapsed/Refractory IDH1+ Acute Myeloid Leukemia (AML)

NCT04250051 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT04250051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04250051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Trial of Ivosidenib and FLAG Chemotherapy in Relapsed/Refractory IDH1+ Acute Myeloid Leukemia (AML)
Lead sponsor
Northwestern University
Phase
Phase 1
Overall status
Terminated
Start date
December 21, 2020
Completion date
December 20, 2022
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml), idh1 mutation myeloid neoplasms, newly diagnosed acute myeloid leukemia (aml), recurrent acute myeloid leukemia, recurrent myelodysplastic syndrome, recurrent myeloproliferative neoplasm, refractory acute myeloid leukemia, refractory myelodysplastic syndrome